Zogenix, Inc. v. Apotex Inc. – Fintepla® (Fenfluramine HCl)

Start
Case Name: Zogenix, Inc. v. Apotex Inc., Civ. No. 21-1252-RGA, 2023 WL 5835828 (D. Del. Sept. 8, 2023) (Andrews, J.) – Drug Product and Patent(s)-in-Suit: Fintepla® (fenfluramine HCl); U.S. Patents Nos. 10,478,441 (“the ’441 patent”), 10,478,442 (“the ’442 patent”), and 11,406,606 (“the ’606 patent”)….
By: Robins Kaplan LLP
Previous Story

FTC Proposes Major Updates to Children’s Online Privacy Protection Act

Next Story

Key Considerations for Updating 2023 Annual Report Risk Factors